News – Page 966 – Endpoints News

Three biotechs raise $100M+ in funding for gene therapies, cancer vaccines and more

7 years ago

Months after Imfinzi combo flops, AstraZeneca wins NICE endorsement as lung cancer monotherapy

7 years ago

Little Proteon shares crash into penny stock territory as lead drug flops in PhIII

7 years ago

Sure Hervé Hoppenot took a big cut in compensation after a pipeline disaster. But he still outscored the only woman ...

7 years ago

Illicit drugs are making some big advances in R&D, and Thiel partners at ATAI get a $43M bankroll to fuel drive on ...

7 years ago

Precision Bio wants to show there's a better way to edit genes — and now it has $126M in IPO cash to prove it

7 years ago

We destroyed nearly 8,000 packs of expired Orkambi stock last year, Vertex tells UK MPs

7 years ago

After a 33-year odyssey, Jeffrey Bluestone grabs a ringside seat to watch his drug teplizumab go back into the clinic

7 years ago

Promising to match more NSCLC patient with targeted drugs, Cambridge spinout Inivata readies US launch of liquid ...

7 years ago

Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody

7 years ago

As AI permeates clinical analytics, Perceptive Advisors bets $40M into a storied player in the field

7 years ago

Jim Mellon's Juvenescence takes a chance on tiny upstart run by former Pfizer exec

7 years ago

Louisiana subscribes to Gilead's Netflix-style plan for hep C; Ono is investing millions in a new I/O research ...

7 years ago

Pain free? Meet Cassava, the newest Alzheimer’s player on Nasdaq

7 years ago

FDA’s Oncology Center of Excellence touts 2018 accomplishments

7 years ago

AbbVie gets its first approval for a drug execs believe could be worth up to $5B in annual sales

7 years ago

Eight months after filing for IPO, the maker of China's Ebola vaccine joins HKEX with $161M raise

7 years ago

Eli Lilly joins a troika of Big Pharmas that have tied up to a low-profile biotech with big aspirations in autoimmune ...

7 years ago

France's NASH contender Genfit leaps onto Nasdaq with $135M IPO

7 years ago

Who are the women blazing trails in biopharma R&D? Nominate them for Endpoints' special report

7 years ago

Dutch rare disease biotech ProQR carves out new company dedicated to epidermolysis bullosa

7 years ago

Blockbuster to be? Novartis snags a major win as FDA OKs a top PhIII drug -- will a pricing controversy follow?

7 years ago

Little Aldeyra's shares rocket higher as its first PhIII eye drug trial scores, clearing path to NDA

7 years ago

Promedior makes a 'breakthrough' with PhIII IPF drug; NASH focused NGM Biopharma sets terms for IPO; bluebird bio ...

7 years ago

First page Previous page 963 964 965966967 968 969 Next page Last page